News Center
Featured
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio...
The acquisition of ValenzaBio adds multiple clinical and pre-clinical development programs to ACELYRIN’s robust immunology pipeline, which is led by izokibep.
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Press Release
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read more ACELYRIN, INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Improve with Longer Duration of Therapy
Press Release
ACELYRIN, INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Improve with Longer Duration of Therapy
Read more Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors
Press Release
Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors
Read more ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa
Press Release
ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa
Read more 
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
Press Release
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
Read more ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa
Press Release
ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa
Read more Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors
Press Release
Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors
Read more